Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Dr. Jonathan Hartwell
Matt's Take

The debate over America’s drug-pricing system is built on myths. It’s time to face reality

By Matthew Herper

CRISPR-edited pigs
In the Lab

Creating Pig3.0, the world’s most CRISPR’d animal, raises hopes of transplantable organs

By Sharon Begley

Good/Bad CEO 2017
Adam's Take

Maraganore victorious in best biopharma CEO tally; Vounatsos tops worst list

By Adam Feuerstein

ASH19 sickle cell disease blood sample
Biotech

In a shift toward venture capital fundraising, FORMA Therapeutics brings in $100 million 

By Kate Sheridan

Adenovirus particles
Biotech

Ring Therapeutics is developing a new way to deliver gene therapy

By Jonathan Saltzman — Boston Globe

Bone Marrow Transplant Illustration
Health

Waning treatment for immune deficiency is a warning for all ‘one-and-done’ therapies

By Eric Boodman

ASH19 Gene Therapy Sickle Cell
Biotech

Research pact between Syros Pharma, Global Blood seeks new drugs to treat sickle cell disease

By Adam Feuerstein

Bone marrow transplant
Biotech

Cutting-edge therapies promise one-time cures, but not without risk. Can biotech make them safer?

By Adam Feuerstein

Genome
Biotech

Startup targeting DNA repeats in Huntington’s and other diseases debuts with $59 million

By Jonathan Saltzman — Boston Globe

Alnylam RNAi
Biotech

Alnylam chalks up another win with phase 3 trial of a rare-disease drug

By Kate Sheridan

BAD CEOS
Adam's Take

And now, your nominees for worst biopharma CEO of 2019. Let the voting begin!

By Adam Feuerstein

Ubiome Kit
Biotech

Bankrupt uBiome preliminarily sells patents for 1% of the poop-testing startup’s original valuation

By Erin Brodwin

Artificial intelligence
Biotech

Axsome’s depression drug succeeds in late-stage trial

By Damian Garde

RNA illustration
Biotech

Wave Life Sciences crashes on negative outcome of Duchenne muscular dystrophy study

By Adam Feuerstein

Good CEOs
Adam's Take

Here are the nominees for best biopharma CEO of 2019. Vote for your favorite!

By Adam Feuerstein

Vascepa pill handout
Biotech

FDA approves Amarin fish-oil-derived drug to prevent heart attacks and strokes

By Matthew Herper

Adam's Take

The good, the bad, and the really, really ugly behind Sarepta’s drug approval

By Adam Feuerstein

Sarepta - hearing
Biotech

Biotech veteran Chris Garabedian on Sarepta’s legacy and Biogen’s future at the FDA

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

Cambridge: Sarepta
Biotech

FDA changes course on Sarepta’s once-rejected muscular dystrophy drug

By Damian Garde

Something ventured illo
Biotech

Something Ventured: Akrevia Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?

By Kate Sheridan

Breast Cancer cells
Health

Breast cancer drug picked up by AstraZeneca shrinks tumors in majority of women with common tumor

By Matthew Herper

Omega Funds Entrance
Biotech

In its largest fundraising effort to date, Omega Funds pulls in over $400 million

By Kate Sheridan

Kendall - Longfellow bridge
Biotech

In tight Massachusetts job market, it’s relo for biotech and remote for tech hires

By Scott Kirsner — Boston Globe

Bristol-Myers Squibb
Biotech

Bristol-Myers CMO on cell therapies: ‘This is the best time to be in drug development’

By Adam Feuerstein

ASH 19 - Fluorescent osteoblast cells
Biotech

Constellation’s blood cancer drug shows strong results, but skepticism may not fade

By Adam Feuerstein

Colorful DNA molecule
Biotech

Merck and Sanofi buy smaller cancer drug firms at big premiums, fueling investor excitement

By Matthew Herper

Biotech

Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version

By Adam Feuerstein

Biotech

New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind

By Adam Feuerstein and Damian Garde

Theater curtain
Biotech

Careful stagecraft at Biogen’s big Alzheimer’s reveal cloaked deep divisions

By Rebecca Robbins

Your daily dose of news in health and medicine

Privacy Policy